Adding ribavirin to interferon  -2b for chronic hepatitis C infection
increased virological response and nausea
|
Interferon -2b plus ribavirin (combination therapy) v
interferon -2b alone (monotherapy) at 48 weeks in
chronic hepatitis C virus infection*
|
|
Outcome
|
Combination therapy
|
Mono- therapy
|
RBI (95% CI)
|
NNT (CI)
|
| Virological response |
36% |
18% |
100% (2 to 302) |
6 (3 to 193) |
| Outcomes |
Combination therapy |
Mono- therapy |
RRI (CI) |
NNH (CI) |
| Dose reduction or treatment withdrawal |
32% |
12% |
167% (19 to 520) |
5 (3 to 27) |
| Nausea |
34% |
12% |
183% (27 to 555) |
5 (3 to 18) |
|
| *
RBI=proportional increase in rates of good outcomes between
combination therapy and monotherapy groups; NNT=number of patients
who must receive combination therapy to achieve 1 additional
good outcome; RRI=proportional increase in rates of bad outcomes
between combination therapy and monotherapy groups; NNH=number of
patients who, if they received combination therapy, would lead to
1 additional person being harmed. |
|
[Return to
Article]
table Of Contents
Hepatitis
Central
http://hepatitis-central.com
|
